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Chapter

Osteosarcoma
Gottardo Bianchi, Leticia Gaiero, Nicolas Casales,
Claudio Silveri and Ana C. Belzarena

Abstract
Osteogenic sarcoma is the most common primary bone cancer frequently
affecting children and teenagers. Despite many years of research, little have the
survival rates changed in the last fifty years. Early diagnosis, a complete systemic
treatment program with a good tumor response and adequate margins continue
to be the main determinants of patients’ prognosis in this disease. Neoadjuvant
chemotherapy followed by surgery and subsequent adjuvant systemic treatment
remain the standard of care. Numerous reconstruction options available provide
these patients better function and improved quality of life.
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1. Introduction
Osteosarcoma, also known as osteogenic sarcoma, is a primary bone malignancy
characterized for the production of osteoid, the mineralized portion of bone matrix
[1]. Different from what its name suggests the origin of the tumor is not bone
itself, but mesenchymal stem cells and osteosarcomas can also be found in soft
tissues unrelated to any bone [2]. The incidence is approximately 1000 new cases
each year in the United States [3]. Osteosarcoma is the third most common cancer
in adolescents and is the most frequent primary bone malignant tumor in this age
group. The peak incidence is between the second and third decade of life, although
there is a second peak of patients aged older than 60 years of age [4, 5]. This tumor
can subclassified according to histologic grade, location within the bone and the
histologic characteristics of the matrix, more than 90% are of high grade, intramedullary location conventional ones [6]. The most common histologic subtypes
are osteoblastic, chondroblastic, fibroblastic and telangiectatic. Additionally, these
tumors can be classified as primary or secondary, depending on if the origin is in
normal bone or altered bone due to prior pathology, for example Paget’s disease,
or radiation [7]. From a genetic perspective, osteosarcomas are characterized by
highly disorganized genomic aberrations rather than a constant genetic alteration
commonly found in other tumors [8]. Despite this, it has been linked to alterations
in some specific genetic pathways expressed as syndromes. Such as Li-Fraumeni
syndrome or Rothmund-Thomson syndrome or an alteration of the Rb protein causing retinoblastoma early in life as well as osteogenic sarcomas [9].
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2. Clinical presentation
Osteosarcomas most commonly occur in the metaphysis of long bones, for the
most part around the knee in the distal femur (43%0 or proximal tibia (23%), followed in frequency by the humerus (10%) (Figure 1) [10]. One in ten patients has a
tumor of axial location, most commonly in the pelvis. Tumors of axial location tend
to have a worse prognosis with higher recurrence rates and more advanced stages at
presentation [10–12]. Patients complaint about intermittent pain and swelling, the
pain is known to be severe enough to awake the patient during sleep hours [13]. Pain
of a high intensity can potentially be an indication of an impending pathological
fracture, fact that occurs in up to 10% of these patients [14]. A pathological fracture
may represent a more aggressive tumor and the microRNA profile of tumors that
fractured have been shown to be different that those without a break. Additionally,
tumors that presented with a fracture were associated with a higher risk of metastatic spread as well as a worse prognosis overall [14].
About 20% of osteosarcoma patients have metastatic disease at presentation.
Most of those secondary lesions are in the lung, bone being the second most common spread location [10]. Tumor size has been implicated as a risk factor for lung
spread [15]. When osteogenic sarcoma presents in older population, there is a
more frequent axial location compared to younger patients, being almost 40% of
the elderly patients versus 10% in children and teenagers [16]. Additionally, the
older patients tend to have larger tumors, more frequency of metastatic disease at
presentation and a worse general prognosis with less opportunity for limb salvage
procedures and inability to receive the full systemic treatment protocol as compared
to younger patients [17]. Moreover, when the chemotherapy response seems to

Figure 1.
Fifteen-year-old patient with a left proximal tibia osteosarcoma, presented with local pain and swelling.
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be poorer in these patients with a lower percentage of necrosis noted on the postchemotherapy tumor resection piece [10]. The 5-year overall survival is 50% for the
elderly when surgical treatment is feasible, when surgery is not an option that rate
drops to 8% [18].

3. Staging
The assessment of osteosarcoma patients usually begins with orthogonal plain
radiographs of the site of pain or mass. Plain films usually reveal an aggressive
appearing lesion that prompts more advanced imaging studies such as a CT scan
or ideally an MRI with and without contrast of the entire affected bone. On radiographic imaging the lesions may be more blastic, lytic or mixed pattern depending
on the osteosarcoma subtype. In more advanced cases, there will be cortical permeation and an associated soft tissue component, although this is a more common finding in Ewing’s sarcomas [19]. For purely lytic lesions, radiographic evidence is only
present when a substantial percentage of the bone has been affected (30–50%), thus
the recommendation in cases of persistent symptoms is to proceed with an MRI even
with a negative plain film [20]. Additional findings on radiographs include a wide
area of transition, cortical destruction and a periosteal reaction such as Codman’s
triangle or a sunburnt pattern (Figure 2) [21].
The next imaging study should be a full bone length MRI with and without
contrast of the affected area, this will serve diagnostic and staging purposes as
well, since it has the ability of detecting skip lesions. MRI studies provide information regarding the complete extent of the tumor within the bone, and its closeness
to surrounding structures such as vessels and nerves. Additionally, it provides
information regarding joint invasion, and, extremely important in the pediatric
population, physis involvement by the tumor [22]. This information will dictate the
proposed surgical intervention (Figure 3). After neoadjuvant chemotherapy and
prior to the definitive surgical treatment a new MRI with and without contrast of
the affected bone must be obtained for tumor re-assessment.
Following the initial images, usually proceeds a close or open biopsy of the
lesion for pathology confirmation of the diagnosis and grading of the tumor. It is

Figure 2.
Radiographic images of a patient with a distal femur conventional, central, osteoblastic, high grade
osteosarcoma. The tumor presents a mixed, blastic and lytic, moth-eaten pattern.
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Figure 3.
MRI of the tibia of a 15-year-old patient with an osteoblastic osteosarcoma of the proximal tibia respecting the
physis (D, E). T1-weighted sequence (A), stir sequence (B) and T1-fat suppressed post contrast sequence (C).

paramount that the biopsy is performed by a surgeon specialized and with experience in bone tumors, so that it can be done following important principles inherent
to the specialty and have those not be respected it can potentially hinder the
possibility of a limb salvage procedure for the patient [23].
Once the diagnosis of osteosarcoma has been confirmed, the next step is to proceed with staging of the patient. Approximately, 20% of patients debut with stage
IV cancer [24]. Osteosarcomas are known to spread most commonly to lungs, 80%
of the metastases, followed by bones (10%) [25, 26]. Therefore, the next imaging
studies will be directed to assess the most common sites of spread. The lung assessment is performed with a non-contrasted chest CT and the bone staging can be
performed by a bone scan or, more recently, with a PET-CT scan (Figures 4 and 5).
4
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Figure 4.
Non-contrasted chest CT depicting peripheral lung nodules (circled) consistent with metastatic osteosarcoma.

Figure 5.
Tecnecium-99 bone scan of a patient with a distal femur osteosarcoma. No other bone lesions were present.

Patients with metastatic disease at presentation have a worse prognosis than those
with localized disease having an overall survival at 5 years of 40% or less [27]. Bone
metastases have a particularly worse prognosis with higher rates of local recurrences
and an overall survival of 13% [26].
Additional studies prior to the start of treatment, will be oriented at making a
basal assessment of organs potentially affected by chemotherapy. Consequently,
the patient will obtain an echocardiogram, kidney function studies, hemogram and
complete metabolic panel as well as an audiology test [13]. Additionally, patients
should be referred for fertility counseling since the systemic treatment is known to
decrease the chances of conceiving even many years after the finalization of chemotherapy. Male patients present with particularly worse chances of conceiving than
females and the cumulative dose of the drugs used seem to be the most important
determinant factor to predict the ability to conceive after treatment [28].

4. Treatment
Currently, the treatment of localized osteogenic sarcoma is the same, independent of subtype and despite its different behaviors and genetic profiles, and
includes a plan of neoadjuvant chemotherapy, followed by local treatment with
5
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surgical resection with a subsequent round of adjuvant chemotherapy [29]. This
plan was first implemented in the 1970’s and improved long-term survival rates
from its original 20% to the current 70%, which has remained unchanged for the
past five decades [30]. The three main reasons for treatment failure are local recurrences, distant disease spread and the development of drug resistance [31].
Systemic treatment for young patients includes two cycles of 5 weeks with high
dose methotrexate, doxorubicin and cisplatin (MAP) [32]. Once the neoadjuvant
cycle has finalized new imaging studies are obtained and the surgical procedure is
planned. The resection piece is afterwards analyzed by the pathologist who must
inform the percentage of necrosis, a key factor of prognostic significance and a
proxy for the tumor chemotherapy response [33]. Following local treatment, 3 to
6 cycles of the same drug regimen (MAP) are given to the patient.
Before the implementation of chemotherapy as part of the treatment plan of
these patients, even the ones with localized disease, most patients underwent a
limb amputation, and despite this aggressive procedure still had poor survival rates.
Nowadays, the standard of care for most patients is a limb salvage procedure which
has shown similar survival rates to an amputation when systemic treatment was
added with a much-improved function and quality of life [34, 35]. The main goal of
limb salvage procedures is to completely resect the tumor while preserving important structures for the limb survival as well as the patient’s function. Several studies
have addressed the importance of achieving adequate margins in a resection as a
determinant factor for the feasibility of the limb salvage option [33, 36, 37]. Local
recurrences, which occur in 10–15% of these patients, has been linked to the margin
adequacy as a predicting factor [38].
Once a decision has been made regarding the limb salvage procedure, several
options present in terms of reconstruction alternatives, all with their specific
advantages and disadvantages. Resection and reconstruction with an endoprosthetic
device, a non-biologic option, is the main trend worldwide currently (Figure 6).
While the biologic alternatives include allografts, vascularized fibula, distraction
osteogenesis or recycled and sterilized bone autograft [39–43]. The latter can be
achieved through several different techniques such as pasteurization, irradiation,
autoclave or most recently the use of liquid nitrogen [44].
Endoprosthetic reconstructions have shown good results in terms of function at
short and medium-term. Among its disadvantages it is its high cost, low accessibility in some countries and limited survival (50–76% at 10 years) with a high rate of

Figure 6.
Distal femur osteogenic sarcoma resection and reconstruction with a distal femur endoprosthetic device
non-cemented.
6

Osteosarcoma
DOI: http://dx.doi.org/10.5772/intechopen.96765

reoperation specially in pediatric patients, an age where primary bone malignant
tumors are most frequent [45]. Allografts require a bone bank with matching bone
pieces. Furthermore, allografts have the potential to transmit diseases and, in some
cases, patient acceptance may be an added obstacle [46]. Bone transport is a lengthy
complex treatment with multiple surgical procedures usually involved [43].

Figure 7.
Case of a 15-year-old male with an osteoblastic osteosarcoma abutting the proximal tibial physis, treated with
limb salvage surgery with liquid nitrogen pretreated bone tumor autograft. Careful surgical planning allowed
the proximal physis to be preserved.
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Figure 8.
Radiographic image depicting a pathological fracture through a distal femur osteosarcoma with displacement
and shortening of the distal fragment.

Frozen autografts recycled in liquid nitrogen are a biologic solution with the
advantages of low cost, easy access, complete removal of viable tumor, bone
morphogenic protein preservation, osteoconduction and osteoinduction properties
maintained, perfect matching at the osteotomy site, does not require a bone bank,
allows reattachment of tendons and ligaments, no disease transmission and no graft
rejection (Figure 7) [47]. Among its disadvantages, the bone piece cannot be sent
for full pathology analysis and thus provide the information about the percentage of
necrosis obtained after systemic treatment in the indicated cases. Nonetheless, the
surrounding soft tissues which are resected prior to submerging the piece in LN are
sent to pathology. This technique accomplishes full necrosis of the tumoral cells and
prior studies have shown that the soft tissue resection prior to the sterilization in
LN is representative of the tumor response to chemotherapy [48]. Additionally, this
procedure has shown no difference in terms of bone resistance to compression when
compared to unfrozen bone. This allows for the initial resistance of the reconstruction, being comparable or even superior to allografts [48].
One particular scenario, the treating orthopedic oncologist should be aware of is
the case of an osteosarcoma with a pathological fracture at presentation. Fractures
through an osteogenic sarcoma can occur in up to 10% of the cases (Figure 8) [14].
In the past, this circumstance used to be a contraindication for a limb salvage procedure and patients were indisputably recommended for an amputation. Nowadays,
even though those patients tend to present a worse prognosis, a limb salvage
procedure is considered an option with similar recurrence rates when compared to
amputations [49]. Prior studies presented the hypothesis that these patients may
have a worse outcome due to a hematoma formation at the fracture site, with tumor
cell dissemination [50]. Although the ideal treatment is controversial, some authors
recommend stabilization of the fracture, which could be achieved by casting, external fixation or limited internal fixation followed by neoadjuvant chemotherapy,
subsequent definite surgical treatment and adjuvant systemic treatment [51, 52].
Radiotherapy has a role for unresectable tumors or in cases of positive margins
to help with local control. The Cooperative Osteosarcoma Study Group (COSS) has
presented promising results for the case of unresectable osteosarcomas of the spine
and pelvis where the treatment with radiation with a curative intent improved the
5-year survival from 0 to 29% [53, 54]. Additional studies have shown radiation
is well tolerated by the patients and can achieve up to 76% local control rates [55].
These findings seem to indicate osteosarcomas do have at least a moderate response
8
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to radiotherapy, when in the past it used to be considered a radiotherapy resistant
tumor. Supplementary indications for radiotherapy include symptom palliation and
this treatment modality has shown to improve patients’ symptoms such as pain in
case of unresectable tumors [56].
Current investigation trials are in place to uncover targetable mutations that
could also have prognostic implications as well studies to assess a potential role for
immunotherapy in osteosarcoma patients [57]. Specifically, Cabozantinib, a tyrosine kinase inhibitor used for thyroid and renal cell cancers, has shown anti-tumor
activity as well as a good tolerance and is currently under investigation through
multicentre trials [58].

5. Conclusion
Osteosarcoma, the most common primary bone malignancy in children and
adolescents, has come a long way since its initial approach where all patients underwent an amputation prior to the 1970’s. Current systemic treatment options along
the myriad of reconstruction alternatives, have allowed these patients to benefit
from better survival rates and improved function and quality of life. Nonetheless,
the overall survival rates have remained stable for the past 50 years, a disappointing number when compared to other malignancies’ statistics, suggesting more
resources and research are needed to continue enhancing the outcomes of patients
suffering from this cancer.
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